Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-03-06 Capital/Financing Update
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a change in shareholding and designation of a new promoter following a share purchase agreement. It details the transfer of shares and the new promoter status of Nirma Limited. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management discussion. The content is an update on capital structure and ownership changes, specifically about share transfer and promoter designation. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes.
2024-03-06 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges referencing a share purchase agreement and the sale of equity shares representing 75% of the company's capital. It is a disclosure pursuant to Regulation 30(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosure obligations for listed companies. The document is short (2097 characters) and serves as an update on a transaction rather than a full report or detailed financial statement. It does not contain financial data or detailed analysis but is an announcement of a capital transaction related to share ownership change. Therefore, it fits best under Capital/Financing Update (CAP).
2024-03-06 English
Public Announcement-Open Offer
Regulatory Filings
2024-02-14 English
Monitoring Agency Report
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges referencing a Monitoring Agency Report for the quarter ended December 31, 2023. It cites compliance with SEBI regulations related to listing obligations and disclosure requirements, specifically concerning the utilization of IPO proceeds. The document is relatively short (2776 characters) and appears to be an announcement or submission of a monitoring report rather than the report itself. There is no detailed financial data or comprehensive analysis present in the text. Given these factors, the document fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-02-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated February 12, 2024, addressed to stock exchanges (NSE and BSE) regarding recommendations made by the Committee of Independent Directors under Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It references an open offer price made by an acquirer (Nirma Limited) and mentions publication of these recommendations in newspapers. The content is an official announcement related to a takeover offer and the independent directors' recommendations to shareholders. This fits the category of a Regulatory Filing (RNS) because it is a formal regulatory announcement related to a takeover but does not itself constitute a merger filing (MA) or tender offer document. It is not a full merger communication or proxy solicitation, nor is it a financial report or voting result declaration. The document is also not a report publication announcement since it contains substantive content and is not merely announcing availability of a report. Therefore, the best classification is Regulatory Filings (RNS).
2024-02-12 English
Updates
Regulatory Filings
2024-02-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.